首页> 外文期刊>International journal of clinical pharmacy. >Is a high maintenance dose of clopidogrel suitable for overcoming clopidogrel resistance in patients?
【24h】

Is a high maintenance dose of clopidogrel suitable for overcoming clopidogrel resistance in patients?

机译:高维持剂量的氯吡格雷是否适合克服患者的氯吡格雷抵抗力?

获取原文
获取原文并翻译 | 示例
       

摘要

Background A double maintenance dose of clopidogrel at 150 mg daily has been suggested as an effective alternative treatment for patients who have clopidogrel resistance. Objective To determine if a double maintenance dose of clopidogrel can overcome the low drug response rate observed in patients who have clopidogrel resistance while on a 75 mg daily standard maintenance dose of clopidogrel. Methods A retrospective analysis was conducted in South Korean patients who underwent a platelet function test and received a double maintenance dose of clopidogrel at a secondary medical institution between January 2011 and June 2012. The primary endpoint was to assess clopidogrel response using an adenosine diphosphate test after a double maintenance dose of clopidogrel. The secondary endpoint was the presence of factors that could affect response to clopidogrel. Results Of 389 patients identified, 77 patients were eligible for this study. Values from the adenosine diphosphate test decreased significantly in 63 patients (82 %) after a double maintenance dose of clopidogrel (p < 0.001). A total of 37 patients (48 %) overcame clopidogrel resistance. Concurrent disease appeared to be a contributory factor in clopidogrel resistance. Conclusion A double maintenance dose of clopidogrel at 150 mg daily was associated with a reduction in adenosine diphosphate-induced platelet aggregation in South Korean patients who previously exhibited clopidogrel resistance.
机译:背景技术对于患有氯吡格雷耐药的患者,建议每日两次维持剂量的氯吡格雷150 mg作为有效的替代治疗。目的确定氯吡格雷双重维持剂量能否克服氯吡格雷抵抗性患者每天服用75毫克氯吡格雷标准维持剂量时观察到的低药物反应率。方法回顾性分析2011年1月至2012年6月间在韩国二级医疗机构接受血小板功能测试并接受双维持剂量氯吡格雷治疗的韩国患者。主要终点是在接受抗凝剂后用二磷酸腺苷测试评估氯吡格雷反应氯吡格雷的双倍维持剂量。次要终点是可能影响氯吡格雷反应的因素的存在。结果确定的389例患者中,有77例符合条件。双重维持剂量的氯吡格雷后,63例患者(82%)的二磷酸腺苷检测值显着降低(p <0.001)。共有37例患者(48%)克服了氯吡格雷耐药性。并发疾病似乎是氯吡格雷抵抗的一个促成因素。结论在韩国先前曾表现出氯吡格雷抵抗力的韩国患者中,氯吡格雷每日两次维持剂量150 mg与二磷酸腺苷诱导的血小板聚集减少有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号